Autoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: a systematic review-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Autoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: a systematic review

Published:2020-11-16 Issue:6 Volume:70 Page:1527-1540
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Zhao Zhe,Wang Xinfeng,Bao Xiu-qi,Ning Jingwen,Shang Meiyu,Zhang Dan^ORCID

Funder

National Natural Sciences Foundation of China

Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences

Chinese Academy of Medical Sciences Fundamental Research Funds for the Central Universities

Drug Innovation Major Project

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

https://link.springer.com/content/pdf/10.1007/s00262-020-02699-1.pdf

Reference61 articles.

1. Gibney GT, Weiner LM, Atkins MB (2016) Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol 17:e542–e551. https://doi.org/10.1016/s1470-2045(16)30406-5

2. Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, Izzeddine H, Marabelle A, Champiat S, Berdelou A, Lanoy E, Texier M, Libenciuc C, Eggermont AMM, Soria J-C, Mateus C, Robert C (2016) Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 13:473–486. https://doi.org/10.1038/nrclinonc.2016.58

3. Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X, Shen C, Duma N, Vera Aguilera J, Chintakuntlawar A, Price KA, Molina JR, Pagliaro LC, Halfdanarson TR, Grothey A, Markovic SN, Nowakowski GS, Ansell SM, Wang ML (2019) Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol 5:1008–1019. https://doi.org/10.1001/jamaoncol.2019.0393

4. Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, Tolaney SM (2018) Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol 4:173–182. https://doi.org/10.1001/jamaoncol.2017.3064

5. Husebye ES, Anderson MS, Kampe O (2018) Autoimmune polyendocrine syndromes. N Engl J Med 378:1132–1141. https://doi.org/10.1056/NEJMra1713301

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research hot spots and trends in endocrine-related adverse events caused by immune checkpoint inhibitors: a bibliometric analysis and visualization research;Frontiers in Endocrinology;2024-04-15

2. Challenges and pitfalls in the management of endocrine toxicities from immune checkpoint inhibitors: a case presentation of synchronous thyrotoxicosis and primary adrenal insufficiency in a melanoma patient;Hormones;2024-02-29

3. Clinically Approved Monoclonal Antibodies–based Immunotherapy: Association With Glycemic Control and Impact Role of Clinical Pharmacist for Cancer Patient Care;Clinical Therapeutics;2024-01

4. Research Advances of Immune Checkpoint Inhibitors Related Endocrine Adverse Events;Advances in Clinical Medicine;2024

5. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024;Diabetes Care;2023-12-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3